

Curriculum Vitae

Prof. Dr Iris Löw-Friedrich

Academic degree: Dr. med. University of Frankfurt/Main

Occupation: Chief Medical Officer, UCB S.A., Brussels, Belgium;
Clinical professor for internal medicine, University of Frankfurt am Main Medical School, Frankfurt am Main/Germany (since 2000)

Place of residence: Ratingen/Germany

Personal data

Year of birth: 1960

Nationality: Deutsch

Member of the Supervisory Board of Evotec SE

First appointment to the Supervisory Board of Evotec SE: 17 June 2014

Appointment to Chairwoman of the Supervisory Board of Evotec SE: 15 June 2021

End of term: End of Annual General Meeting 2024

Education

1985 University of Frankfurt/Main
Conferral of a doctorate (Dr. med.)

1979 – 1985 University of Frankfurt/Main
Study of medicine

Professional career

Since 2008 UCB S.A.
Chief Medical Officer and Executive Vice President Development and Medical Practices

2001 – 2009 Schwarz Pharma AG
Member of the Executive Board, Global responsibility for research and development

2000 – 2001	BASF Pharma
	Vice President Global Projects
Since 2000	University of Frankfurt/Main
	Clinical professor for internal medicine
1992 – 2000	Hoechst AG
	Various positions, most recent position of Vice President Clinical Development

Appointments to other statutory supervisory boards and comparable national and international supervisory bodies of commercial enterprises

Fresenius SE & Co. KGaA (Member of the Supervisory Board)

TransCelerate BioPharma Inc (Member of the Supervisory Board)

PhRMA Foundation (Member of the Board of Directors)

Other significant activities besides the Supervisory Board mandate

n/a

Relevant knowledge, skills and experience

Since March 2008, Prof. Dr Iris Löw-Friedrich is serving as Chief Medical Officer and Executive Vice President Development and Medical Practices of UCB S.A., Brussels (Belgium). From 2001 to 2009, Prof. Dr Löw-Friedrich was a member of the Executive Board of Schwarz Pharma AG, Monheim am Rhein, with global responsibility for research and development. From 2000 to 2001, she served as Vice President Global Projects at BASF Pharma, Ludwigshafen. From 1992 to 2000, Prof. Dr Löw-Friedrich held various positions in the area of drug development at Hoechst AG, Frankfurt am Main, lastly as Vice President Clinical Development at Hoechst Marion Roussel/Aventis, Bridgewater, NJ, USA.

Since April 2014, she has been Member of the Board of Directors at TransCelerate BioPharma Inc (Chairman of the Board of Directors from September 2015 until September 2017). TransCelerate BioPharma Inc is a non-profit organisation with membership of 20 major life science companies, including UCB.

Since May 2016, Prof. Dr Löw-Friedrich has been serving as Member of the Supervisory Board of Fresenius SE & Co. KGaA. Prof. Dr Löw-Friedrich began her career in 1985 as a physician in the field of internal medicine at the University of Frankfurt/Main, Medical School, where she has also been a clinical professor for internal medicine since 2000. She studied medicine at the University of Frankfurt/Main, receiving her doctorate from this university in 1985.

Due to her clinical expertise, Prof. Dr Löw-Friedrich ideally complements the future Supervisory Board of Evotec SE and expands its range of competences.



Personal or business relationships in accordance with items C.6 to C.12 of the German Corporate Governance Code

Prof Dr Iris Löw-Friedrich (Chief Medical Officer and Head of Development & Medical Practices of UCB S.A.) is independent in the opinion of the Company. Her position on the Executive Board of UCB S.A., which has a business relationship with Evotec SE, does not constitute dependency. Business relationships constitute a material and prolonged conflict of interest only in exceptional cases. The Supervisory Board has no influence on the volume of orders or the continuation or expansion of business relationships. This is the responsibility of the Management Board of Evotec SE, which not only represents the Company (section 78 of the German Stock Corporation Act (AktG)), but also makes decisions on these matters under its own responsibility (section 76, paragraph 1 of the German Stock Corporation Act (AktG)). There is also no intersecting executive body position.

Latest update: June 2021